KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $5.9 billion.

  • Abbott Laboratories' Other Accumulated Expenses rose 834.72% to $5.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year increase of 834.72%. This contributed to the annual value of $5.1 billion for FY2024, which is 514.57% down from last year.
  • Abbott Laboratories' Other Accumulated Expenses amounted to $5.9 billion in Q3 2025, which was up 834.72% from $5.7 billion recorded in Q2 2025.
  • Abbott Laboratories' 5-year Other Accumulated Expenses high stood at $5.9 billion for Q3 2025, and its period low was $5.1 billion during Q2 2024.
  • Its 5-year average for Other Accumulated Expenses is $5.4 billion, with a median of $5.4 billion in 2022.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2729.43% in 2021, then crashed by 934.35% in 2024.
  • Quarter analysis of 5 years shows Abbott Laboratories' Other Accumulated Expenses stood at $5.2 billion in 2021, then grew by 12.82% to $5.8 billion in 2022, then dropped by 7.24% to $5.4 billion in 2023, then dropped by 5.15% to $5.1 billion in 2024, then rose by 14.33% to $5.9 billion in 2025.
  • Its last three reported values are $5.9 billion in Q3 2025, $5.7 billion for Q2 2025, and $5.6 billion during Q1 2025.